Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Qureight to support Mediar Therapeutics' Phase 2 trial of MTX-474 in diffuse cutaneous Systemic Sclerosis

Qureight, an end-to-end imaging CRO that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, and Mediar Therapeutics (Mediar), a clinical-stage biotechnology company advancing first-in-class therapies designed to halt fibrosis, today announced Qureight's AI-powered 3D quantitative imaging analytics platform and services will be used to support Mediar's Phase 2 EncompaSSc clinical trial.

From Society for Laboratory Automation and Screening (SLAS) 13 May 2026

AI-based generative framework create all-atom models of proteins in motion

Many drug and antibody discovery pathways focus on intricately folded cell membrane proteins. When molecules of a drug candidate bind to these proteins, like a key going into a lock, they trigger chemical cascades that alter cellular behavior.

13 May 2026

New malaria vaccine offers long-lasting protection without refrigeration

Malaria is a deadly disease killing more than half a million people every year, but a new vaccine is showing promise as it not only offers long-lasting strong protection but also inhibits transmission of malaria by mosquitos.

13 May 2026

New antibody therapy promotes nerve regeneration after spinal cord injury

An international research group recently demonstrated that the antibody NG101 promotes the regeneration of damaged spinal cord tissue.

12 May 2026

Nuclera launches antibody triage service to advance AI-driven antibody discovery

Nuclera, the biotechnology company enabling rapid access to high-quality proteins, today announced the launch of its antibody screening service to streamline the transition from antibody hit generation to lead selection.

From Nuclera 11 May 2026

Rockefeller scientists reveal how HIV strains escape broadly neutralizing antibodies

Broadly neutralizing antibodies (bNAbs) are among the most promising new treatments for HIV, offering the potential to forego traditional daily dose of antiretroviral drugs.

11 May 2026

Suppressing TGF-β signaling reactivates dormant bone cells to treat osteoporosis

Osteoporosis, a common skeletal disorder, is marked by reduced bone mass and deterioration of bone microarchitecture, making bones more porous and prone to fractures.

8 May 2026

Infectious H5N1 virus detected in dairy farm air

Findings from California dairy farms show H5N1 in air and wastewater, indicating overlooked transmission routes and implications for outbreak management.

8 May 2026

The power of organoids in speeding up lifesaving drug development

Organoids are miniature tissue or organ models formed by stem cells (including pluripotent stem cells, tissue-specific adult stem cells, etc.) or progenitor cells in an in vitro three-dimensional culture system, which possess structural features and partial functions analogous to their corresponding in vivo organs. In 2009, the Hans Clevers laboratory developed the first intestinal organoid, marking the inception of organoid-based disease modeling.

8 May 2026

Blocking TGF-beta may enhance osteoporosis bone regeneration therapies

A recent mouse model based study suggests that blocking TGF-β may improve osteoporosis treatment by helping quiescent osteoblasts in inactive bone surfaces return to an active state.

7 May 2026

JAYseq test delivers rapid genomic profiling for multiple myeloma patients

The Translational Genomics Research Institute (TGen), part of City of Hope, today announced the launch of JAYseqTM, a clinical whole-genome sequencing (WGS) test specifically for multiple myeloma.

7 May 2026

Scientists identify powerful human antibodies capable of neutralizing measles virus

Scientists at La Jolla Institute for Immunology (LJI) are the first in the world to characterize human antibodies capable of neutralizing measles virus.

7 May 2026

YAP1 expression drives chemotherapy resistance in small cell lung cancer

Researchers from The University of Texas MD Anderson Cancer Center have discovered that some cancer cells express the YAP1 protein only after treatment with chemotherapy, allowing them to survive by becoming more invasive and leading to treatment resistance with eventual relapse in patients with small cell lung cancer (SCLC).

5 May 2026

Study highlights breakthrough in overcoming diminishing returns of sequential IBD therapies

For patients with Crohn's disease or ulcerative colitis who have exhausted other treatment options, a new combination therapy is showing results that offer hope for one of medicine's most treatment-resistant populations, according to findings from two studies to be presented today at Digestive Disease Week® (DDW) 2026.

5 May 2026

Three cognitive trajectories identified in preclinical Alzheimer’s disease

Cognitive decline in Alzheimer's disease differs substantially from one person to the next and is not well predicted by existing medical tests.

27 Apr 2026

Kenyan bat coronavirus uses human CEACAM6 to enter cells, raising spillover concerns

Researchers screened a phylogenetically diverse panel of alphacoronavirus spike proteins and found that a heart-nosed bat coronavirus from Kenya can use human CEACAM6 to enter cells.

23 Apr 2026

New antibody mechanism selectively suppresses harmful immune responses

The immune system is our frontline protection against infection, continually searching for and destroying unknown pathogens.

22 Apr 2026

Low-dose nivolumab injections shrink precancerous oral lesions

Direct injection of a low dose of the immune checkpoint inhibitor nivolumab into precancerous oral lesions significantly reduced lesion size and risk of cancer progression, sparing most patients from surgery.

21 Apr 2026

CAR-PRISM trial reports promising results in high-risk smoldering multiple myeloma

Results of the single-center, phase 2 CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to investigate Chimeric Antigen Receptor (CAR) T-cell therapy in patients with high-risk smoldering multiple myeloma, showed that all 20 patients were negative for minimal residual disease (MRD) within two months of treatment and remained MRD-negative after a median of 15.3 months of follow-up, and none experienced high-grade side effects, according to results presented at the AACR Annual Meeting 2026, held April 17-22, in San Diego, Calif.

21 Apr 2026

Early immune responses linked to broadly neutralizing antibodies against HIV

Some people living with HIV develop antibodies capable of neutralizing many different strains of the virus. New research links this to immune responses that occur early in infection.

21 Apr 2026

Antibody News and Research

Further Reading

Qureight to support Mediar Therapeutics' Phase 2 trial of MTX-474 in diffuse cutaneous Systemic Sclerosis

AI-based generative framework create all-atom models of proteins in motion

New malaria vaccine offers long-lasting protection without refrigeration

New antibody therapy promotes nerve regeneration after spinal cord injury

Nuclera launches antibody triage service to advance AI-driven antibody discovery

Rockefeller scientists reveal how HIV strains escape broadly neutralizing antibodies

Suppressing TGF-β signaling reactivates dormant bone cells to treat osteoporosis

Infectious H5N1 virus detected in dairy farm air

The power of organoids in speeding up lifesaving drug development

Blocking TGF-beta may enhance osteoporosis bone regeneration therapies

JAYseq test delivers rapid genomic profiling for multiple myeloma patients

Scientists identify powerful human antibodies capable of neutralizing measles virus

YAP1 expression drives chemotherapy resistance in small cell lung cancer

Study highlights breakthrough in overcoming diminishing returns of sequential IBD therapies

Three cognitive trajectories identified in preclinical Alzheimer’s disease

Kenyan bat coronavirus uses human CEACAM6 to enter cells, raising spillover concerns

New antibody mechanism selectively suppresses harmful immune responses

Low-dose nivolumab injections shrink precancerous oral lesions

CAR-PRISM trial reports promising results in high-risk smoldering multiple myeloma

Early immune responses linked to broadly neutralizing antibodies against HIV

Industry Focus eBook - Cell biology (5th edition) eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery